Skip to main content

Menu

British National Formulary May 2024 Update

This update contains 8 significant changes, 5 dose changes, 5 new monographs, 2 new preparations and 2 deleted monographs.

Significant Changes:

  • Budesonide: update to dosing for modified-release capsules.
  • Codeine phosphate linctus (codeine oral solutions): reclassification to prescription-only medicine [MHRA/CHM advice].
  • Hydrocortisone: updated indication oral and perioral lesions to aphthous ulcers.
  • Hyoscine butylbromide: update to important safety information.
  • Malaria, prophylaxis: updated guidance.
  • Pneumococcal vaccine: updated guidance for immunisation.
  • Pseudoephedrine hydrochloride: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) [MHRA/CHM advice].
  • Vaccination, general principles: updated guidance for immunisation of individuals with asplenia, splenic dysfunction, or complement disorders.

Dose Changes:

  • Acetylcysteine [update to dosing for paracetamol overdosage].
  • Lansoprazole [update to dosing for Zollinger–Ellison syndrome].
  • Pantoprazole [update to dosing for Zollinger–Ellison syndrome].
  • Paracetamol [update to weight ranges for intravenous paracetamol].
  • Pneumococcal polysaccharide conjugate vaccine (adsorbed) [update to dosing].

New Monographs:

  • Enspryng® [satralizumab].
  • Evkeeza® [evinacumab].
  • SimAlvia® [alverine with simeticone].
  • Tepkinly® [epcoritamab].
  • Zilbrysq® [zilucoplan].

New Preparations: Kinpeygo® [budesonide]; Otinova® [aluminium acetate].

Deleted Monographs: Chloroquine with proguanil; Proguanil hydrochloride.